• Trxade announces pricing of a firm commitment public offering of 806,452 shares of its common stock
• Proceeds to be used as working capital and to fund future acquisitions
• Company’s B2B online purchasing platform currently has 11,900 pharmacies registered and is registering 100+ New pharmacies per month

Trxade Group Inc. (NASDAQ: MEDS), an integrated drug delivery, procurement, and healthcare platform that offers healthcare buyers and sellers of pharmaceuticals increased profit margins, announced that its common stock has begun trading on the Nasdaq Capital Market under new ticker symbol ‘MEDS’, as of February 13, 2020. The company’s common stock will cease trading on the OTCQB.

The company also announced the pricing of a firm commitment public offering of 806,452 shares of its common stock at $6.50 per share. Trxade Group granted a 45-day option to underwriters to buy up to an additional 120,967 shares of common stock to cover overallotments, or post-reverse stock split. The offering was expected to close on or around February 18 (http://nnw.fm/nfIU9) (http://ibn.fm/keqve).

Before deducting offering expenses and underwriting reductions, Trxade Group expects gross proceeds of $5.2 million from the sale of common stock in the offering. The company intends to use the net proceeds from the offering for general purposes and working capital, as well as to possibly fund acquisitions of other products, companies or technologies.

Dawson James Securities, Inc., Dougherty & Company LLC, and View Trade Securities, Inc. are acting as the underwriters of the offering.

Trxade has developed a proprietary web-based e-commerce platform (S2P – Supplier to Pharmacy) that enables trade among pharmaceutical, accessory, and service buyers and sellers. The platform currently has about 11,500 pharmacies as registered users, through which it reaches between 12 million and 15 million patients. The company aims to reach most, if not all, of the estimated 24,000 independent pharmacies currently operating in the U.S., with combined pharmaceutical purchases of $93 billion per year. The U.S. pharmaceutical industry, which is worth $330 billion, is comprised of 1,500 state-licensed suppliers and more than 65,000 pharmacy facilities, 24,000 of which are independent.

The platform offers multiple benefits such as significant discounts that contribute to a 7-10 percent decrease in the annual purchase expenses for pharmacies; no registration and transaction fees for pharmacies; a simple and intuitive interface that helps pharmacies compare prices and select the best offer with guaranteed security for purchases and payments. Revenue is generated from two primary sources: the growing number of registered users and an increase in the platform’s utilization rate among registered users. The company is adding over 100 pharmacies to its platform per month and has plans to soon provide access to other healthcare providers, such as hospitals, veterinary clinics and long-term care facilities.

The U.S. healthcare market is currently valued around $4 trillion. As the general population ages, further growth is expected, which in turn will have increasing impact on consumers as out-of-pocket expenses rise as well. Trxade aims to lower prescription drug costs by attacking the inefficient value chain, delivering drugs directly to independent pharmacists and consumers, and offering efficient purchasing and price transparency. Its integrated drug procurement, delivery and healthcare platform also delivers increased profit margins.

Founded in 2010, the company is comprised of three synergistic operating platforms: the B2B trading platform with 11,900 registered pharmacies, licensed virtual Wholesale and Mail Order Pharmacy capabilities including the mobile app DelivMeds, as well as the newly acquired assets of Bonum Health, a telemedicine platform.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://nnw.fm/MEDS http://ibn.fm/MEDS

• Sharing Services Global Corporation offers entrepreneurial opportunities, broad range of products and services for contemporary consumers
• SHRG will be holding the Happiness Revolution Convention 2020 this spring
• Sharing Services Global facilitates Blue Ocean Strategy, symbolic of immense opportunity in the entrepreneurial space

Sharing Services Global Corporation (OTCQB: SHRG) is a holding company that owns, operates or controls an interest in companies specializing in the direct-selling industry. The company’s emphasis is on direct selling, and SHRG has grown by thousands of independent sales representatives over the past year. Through one of its strategic avenues to help empower its growing body of Elepreneurs, the company recently announced its 2020 Happiness Conference, slated to take place April 16-19 in Grapevine, Texas.

Planned and executed by SHRG’s wholly owned subsidiary, Elepreneurs LLC, the Happiness Revolution Convention 2020 is designed specifically to benefit, support and encourage the company’s international network of independent representatives, called Elepreneurs. Elepreneurs LLC provides basic and advanced programs for new and experienced entrepreneurs who are concentrating on their direct-sales careers.

Held at the Gaylord Texan, the conference will feature invaluable networking opportunities, as well as meetings with field leaders and the SHRG home office team. Other conference highlights include the launch of new products, new tools and new apparel for the benefit of Elepreneurs; expert training for Elepreneurs in the areas of skills, social media and leadership; and the opportunity to learn from Ray and Jessica Higdon, creators of hit reality show ‘Play to Win’, where motivated contestants tackle sales and business challenges to win a life-changing opportunity (http://ibn.fm/VIquj). Additionally, The Happiness Revolution Convention 2020 offers an array of teambuilding and networking activities, including a welcome party, a ‘70s party, memorable entertainment, a family room, and a variety of team events.

Sharing Services Global’s dedication to maximizing shareholder value is evident in the operation of its two main subsidiaries: Elepreneurs LLC, a direct-selling company, and Elevacity Global LLC, a products company. SHRG’s focuses on companies that sell directly to the consumer through independent representatives or that offer services ranging from health and wellness, energy, technology, insurance services, training and media.

As SHRG focuses on organic growth, expanding its ever-growing team of independent sales representatives, recent statistics indicate that the direct-selling model is flourishing. The Direct Selling Association (DSA) noted in its 2019 Direct Selling Growth and Outlook Survey (http://ibn.fm/GP2re), which was released in June 2019, that “the number of people selling products or services using the direct selling model grew 1.6 percent, with more than 6 million U.S. entrepreneurs selling in either on a part-time or full-time basis.” The report further noted that “the U.S. direct selling industry is moving in a very positive direction. Retail sales were strong, thanks largely to the U.S. direct sales force and their ability to attract millions and millions of customers.”

Also fueling that growth for Sharing Services Global is its Blue Ocean Strategy, which empowers entrepreneurs. The Blue Ocean Strategy involves elevating home-based entrepreneurs; generating organic growth; and creating successful independent business leaders. These business leaders – SHRG Elepreneurs – promote the Elevacity line of products to customers.

Elevacity Global manufactures and distributes all products that Elepreneurs market. The health and wellness products contain superior, scientifically backed ingredients designed to stimulate specific happiness hormones referred to as D.O.S.E., dopamine, oxytocin, serotonin, and endorphins (http://ibn.fm/TbEZM). With its product line of elevated health and wellness products, Elevacity Global is a promising revenue stream for SHRG.

Sharing Services Global continues to maintain a strong position in the worldwide direct-selling market. Of note to investors is that the company is experiencing rapid growth with its record-breaking increase in sales in 2019 due to its launch of innovative health and wellness products. Sharing Services Global is set to dynamically leverage the forecast growth for the direct-selling industry and continues to work to elevate its Elepreneurs to greater levels of success.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• SRAX CEO discusses company’s milestone achievements in 2019
• Two flagship products – BIGtoken and SRAX IR – are generating multiple recurring revenue streams
• SRAX is strategically positioned for strong 2020 as proprietary products start contributing to the top line
• Company moves from development cycle to revenue cycle, anticipates 2020 growth

In an exclusive interview with NNW’s Stuart Smith, SRAX Inc. (NASDAQ: SRAX) CEO Chris Miglino discusses the company’s milestone achievements in 2019 as well as its ambitious plans for 2020 to harness the brand recognition built on the emerging regulation underpinning consumer data protection (http://ibn.fm/G72dC).

“That was a big year for us in terms of getting our BIGtoken product out to the market and getting new products out to market in general,” Miglino said, summarizing major developments of 2019. “BIGtoken and SRAX IR came to maturity of being able to start generating revenue this year, and we are excited about that going forward. BIGtoken ended up the year with around 16.5 million users on the platform, all of whom signed up within a year.”

SRAX, a digital marketing and consumer data management technology company, is revolutionizing consumer data collection through a secure and transparent platform called BIGtoken. BIGtoken unlocks the data, helping brands reveal their core customers and the characteristics of those customers across different marketing channels, while at the same time allowing consumers to make money from selling the data they create as part of their digital footprint. In addition, the company developed the SRAX IR platform, which helps public companies communicate with existing shareholders and also reach potential investors by leveraging data on their behavior.

Speaking about SRAX IR, Miglino noted that the product is building a valuable community of public stock issuers, with 35 companies joining the platform. SRAX IR helps public companies manage the relationship with their existing and potential investors by leveraging data on stock buyers’ and sellers’ activities to uncover trends in their behavior over time, and by tracking ROI on investor relations programs. Miglino reports that the product is receiving positive feedback from users as it enables them to better communicate with their investor base.

SRAX is currently in an excellent position as BIGtoken is generating multiple revenue streams from market research, customer activation and customer data segments selling to clients such as Proctor & Gamble, Kraft, Sun-Maid and others, said Miglino, who also described ambitious plans for the future: “We have some amazing plans in 2020 about what we’re going to be launching on the platform. 2019 for us was the year to tee up all the platforms and the technology to start generating revenue, and 2020 is where we’re going to start to see both BIGtoken and SRAX IR start to contribute to the top line for the company.”

Miglino pointed out that the year has already started strong as SRAX announced in January that it partnered with Experian to offer financial services to BIGtoken users (http://ibn.fm/tJawt), a deal that Miglino expects to be a big revenue generator both for SRAX and Experian.

Speaking about SRAX’s outlook for 2020, Miglino said that the company established powerful partnerships with both publishers and marketers to bring people on to the BIGtoken platform. As a result, the company expects an increasing number of consumers to join the platform, while SRAX IR anticipates continued growth of recurring revenue streams. “Both platforms are keyed up now to start contributing to the company financially,” said Miglino. “As we move from the development cycle to the revenue cycle, we are very excited about that.”

With the Q3 results released in November 2019 showing that vertical sales increased 17% year on year while net income reached 1.4 million, the financials reflect that SRAX is on the right track towards achieving these plans (http://ibn.fm/jwGAP). As the company continues its strategic growth, SRAX represents an attractive opportunity for investors seeking to capitalize on early entrance into the lucrative consumer-data space.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Nightfood has superior nutritional profile for mothers-to-be
• Award-winning ice cream increasingly recommended to pregnant women by service providers.
• Nightfood aims to leverage untapped pregnancy market of up to 3 million women to accelerate national supermarket rollout

Nightfood Holdings Inc. (OTCQB: NGTF) is changing the conversation around ice cream through its subsidiary Nightfood Inc., creator of an award-winning, nutrient-rich ice cream that is taking the pregnancy community by storm. With its unique and healthier nutritional profile, Nightfood is being recommended to pregnant women by their providers as a better option when pregnancy cravings inevitably hit.

Nightfood is in position to dominate the untapped pregnancy ice cream market, which consists of over 3 million American women at any given time. With over 10,000 new women entering the category every day, company management believes this highly motivated consumer demographic can be an immediate and constant source of new and loyal long-term consumers (http://ibn.fm/A1Ak6). Nightfood CEO Sean Folkson believes Nightfood has an unassailable advantage with this highly desirable consumer segment, stating, “The simple fact is that no other ice cream brand can address the pregnancy market with any integrity, because their formulations and nutritional profiles just don’t align the way Nightfood does.”

Nightfood offers expectant mothers a way to satisfy their biologically driven nighttime cravings while feeling good about what they’re putting into their bodies. Unlike any other brand on the market, Nightfood’s ice cream packs extra calcium, magnesium, zinc, fiber, and protein combined with a lower sugar content—all sought-after characteristics of a prenatal diet.

Formulated by sleep and nutrition experts, Nightfood’s unique ice cream also includes ingredients to fight heartburn and other issues that are particularly important to the needs of pregnant women for high-quality sleep, healthy bone density and nervous system health. With an eye still focused on the broader market, Folkson asserts that the company is not rebranding the product as a “pregnancy” ice cream, stating that “Nightfood remains a mainstream product for over 200 million American men and women,” and that “moms and their families can stick with Nightfood through the years, not just through birth.”

Scientific studies confirm links between pregnancy and ice-cream cravings, with research affirming that these cravings are biologically driven. Since pregnant women have increased nutritional needs required to support their health and growing babies, the cravings may be representative of an increased need for certain micro and macro-nutrients. Dr. Lauren Broch, a Nightfood advisor holding an MS in human nutrition whose practice focuses on women’s health, including pregnancy, remarked, “pregnant women are not going to stop craving and eating ice cream, so let’s help them identify a healthier choice for their needs.”

In addition to landing media coverage on major outlets such as The TODAY Show, the Wall Street Journal, Oprah Magazine, USA Today, the Washington Post and Parents Magazine, Nightfood also engages local efforts to increase brand awareness among expectant mothers by sponsoring events at childbirth education workshops, prenatal exercise studios and other businesses that serve pregnant women.

Nightfood management has pointed out that the velocity with which information spreads within this demographic will allow the Nightfood brand to establish a stronghold very quickly. “From social media groups and blogs to the mainstream media, and local workshops, today’s pregnant women share and consume tremendous amounts of information at lightning fast speeds,” Jessie Trinchard, Nightfood’s sales director, stated in a news release.

With multiple major supermarket chains committed to adding Nightfood in the coming weeks, Nightfood is poised to become the preferred ice cream brand of pregnant women across the country right here in 2020.

Headquartered in Tarrytown, New York, Nightfood is revolutionizing the world of night snacking with its innovative offerings. With an eye on America’s $50 billion nighttime snacking problem, Nightfood is focused on improving the late-night snacking choices of consumers while becoming a national brand with a billion-dollar valuation. With increased brand recognition fostered by the uber-connected pregnancy community, Nightfood indicates significant untapped potential for market penetration.

For more information, visit the company’s website at www.Nightfood.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• SHRG achieves record sales of health and wellness products through direct selling by home-based entrepreneurs
• Expert advisors key to company’s sales success through development of hormone-balancing products that improve mood and sense of well-being
• 2019 record sales continue this year with sales rising each quarter, fueling plans for international expansion

Sharing Services Global Corporation (OTCQB: SHRG), a holding company working through subsidiaries Elepreneurs LLC and Elevacity Global LLC, operates with a strategy of empowering home-based entrepreneurs to sell health and wellness products directly to consumers. The company’s expert leadership supports these individuals, known as Elepreneurs, through training programs that give them the tools needed to achieve business success while elevating the physical and emotional well-being of their customers.

Led by CEO John “JT” Thatch and a team of industry experts in the nutrition, personal development and direct-selling spaces, the company has made the happiness industry a profitable enterprise. According to its 10-Q filed with the SEC (http://ibn.fm/oIYg3), SHRG reported record sales growth in 2019, with sales continuing to grow each quarter (http://ibn.fm/V36EB).

Prior to joining SHRG in March 2018, Thatch had successfully launched, owned and operated several businesses and is an accomplished entrepreneur himself, he has the synergistic ability to support SHRG Elepreneurs through company operations while simultaneously using his knowledge and experience to create shareholder value for the organization.

From human-resource concerns to product creation and direct-sales operations, all aspects of SHRG’s operations are covered by its team of expert advisors across a range of key areas. Leading product development is Kevin Thomas, a 36-year expert in nutritional supplement creation with a robust intellectual-property portfolio.

Direct-sales expertise and training methodology is brought to the company by respected leaders and built around a vision of Shawn Achor, the New York Times best-selling author of The Happiness Advantage and Big Potential, who brings years of experience from working in more than 50 countries and having worked with nearly half of the Fortune 100 companies.

The combined leadership knowledge of SHRG’s management team is reflected in the company’s success, extending forward through each Elepreneur’s personal mission to elevate their customer’s well-being through the sales of the Elevacity product line. Since an individual’s mental and physical well-being is highly dependent on hormone balance, Elevacity addresses these issues through its D.O.S.E. line of products that are based on a unique combination of dopamine, oxytocin, serotonin and endorphins. In addition to these patented supplements, SHRG also offers skin-care products made from natural ingredients for all skin types.

Headquartered out of a 10,000-square-foot facility in Plano, Texas, SHRG has planned for future expansion as the company grows. Customer-service facilities, operations and training rooms, and a video-production suite are currently available onsite with room for growth in each area. In addition, SHRG is looking forward to international expansion. The company’s line of products is currently available in the United States, Canada, New Zealand and Australia.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• CBD Biotech seizing immense opportunities in untapped CBD Chinese market
• CIIX operates both online, physical CBD stores in addition to developing first Chinese, CBD-based social media app
• CIIX’s hemp-based products fully legal in China with plans for further development, Nasdaq IPO this year

ChineseInvestors.com Inc. (OTCQB: CIIX), a leading U.S.-based financial consultancy for Chinese-speaking investors, is positioning its subsidiary, CBD Biotech Inc., as a leader in the Chinese-based CBD market through increased development of legal hemp-based products.

Clinically shown to help with anxiety and stress-related disorders (http://ibn.fm/dbNam), CBD-based products may be helpful for dealing with the coronavirus outbreak, CIIX CEO Warren Wang stated during a recent interview (http://ibn.fm/myK5y). While clarifying that medical help is essential, Wang shared his opinion that CBD products “can help your immune system.” Wang also noted that CBD Biotech Inc. will be “the first one in the public market field inside China selling CBD.”

In partnership with a well-known CBD brand, CIIX currently markets to the massive Chinese-speaking market worldwide through its website ChineseCBDOil.com – one of the world’s first online stores in the Chinese language that provides industrial-hemp-derived, CBD soft gels, capsules and concentrates. In order to support the company’s online efforts, CIIX has developed a Yelp-style mobile app to be used as a platform for Chinese consumers to review and discuss various cannabis products, making it the first marijuana-based social media mobile application for Chinese-speaking customers in the world. In addition to operating online, CIIX also serves the Chinese population of San Gabriel, California, through its retail store.

With few competitors and plenty of room for market dominance, CIIX plans to seize opportunities in the fully legal, hemp-based CBD nutritional and cosmetic product markets in China. While cannabis is still illegal in the country, prohibitory laws do not apply to hemp-based CBD cosmetics. Unaffected by changing regulations, CIIX is able to operate in a stable environment with the freedom to focus investment on the research and development of new CBD products. The company has established a three-year development plan for CBD Biotech in mainland China and has hopes for a Nasdaq IPO in 2020.

With a global Chinese-speaking base that continues to grow, CIIX disseminates investment information through its proprietary financial news media and content platform. The company assists its subscriber base in making informed investment choices through its exclusive service, called the ChineseInvestors Method. This investment strategy integrates personalized advice with web-based tools, empowering Chinese investors to make optimal investment decisions based on their needs and risk profile. All services by the company are offered in both traditional and simplified Chinese-language character sets (http://ibn.fm/NiIwr).

Besides offering its audience of investors real-time market commentary, analysis and educational-related services, the company also provides consulting services to smaller private companies that wish to go public, in addition to advertising, social media, and public relations consulting services.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• Lexaria’s DehydraTECH(TM) drug delivery platform a feasible and healthier alternative to other delivery methods
• The fast-acting, high absorption technology improves dipping experience and consumer satisfaction
• Company expects to more than double its 2019 revenue this year, will pursue a new capital markets strategy to qualify for listing on a nationally recognized U.S. exchange

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms and one of the few companies active in the field of cannabis to have developed formal relationships with Fortune 500 industry leaders, is experiencing strong demand from many companies requesting pre-processed DehydraTECH(TM)-enhanced bulk powders.

The company’s revolutionary drug delivery platform DehydraTECH(TM) accelerates human intestinal cell absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sugars or sweeteners, and other unhealthy practices. It is applicable to a wide variety of bioactive substances, including cannabis and nicotine. Utilization of the DehydraTECH(TM) drug delivery platform increases the absorption levels of CBD in human intestinal cells by 499%. As much as 1,937% more CBD is delivered into animal brain tissue after 8 hours using the enhanced technology in comparison with generic industry MCT coconut-oil formulations, according to recent studies.

Vaping and smoking have been shown to be dangerous methods of delivering drugs. Lexaria developed its technology as a safe and fast delivery method of bioactive substances via oral ingestion by bypassing potentially unhealthy practices such as inhalation. Proven to deliver up to 10 times more active ingredients in comparison to traditional edible, DehydraTECH(TM) is the first platform of its kind that allows users to access the primary benefits of inhalation – speed and efficiency – while circumventing the risks of inhalation.

The company currently has 16 patents granted and more than 60 patent applications worldwide. It is the only company to hold a patent for improved delivery of nicotine and all non-psychoactive and psychoactive cannabinoids, including tetrahydrocannabinol. The platform reduces the time of onset of THC by four times on average (http://ibn.fm/AvVxl).

Lexaria also obtained two patents for treating certain conditions including, but not limited to heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia, and others. The platform has potential applications to assist treatment of the common form of dementia as well as other nervous system diseases.

In 2019, the company finalized a new contractual relationship with a GMP-certified, FDA registered production company to get enhanced DehydraTECH(TM) powders to market in the U.S. with current capacity of roughly 200,000 servings per day (http://ibn.fm/T0TMV).

The versatility and multiple potential applications of the DehydraTECH(TM) drug delivery platform, paired with the proven benefits it offers over other delivery methods, are some of the key factors driving demand and revenue growth for Lexaria Bioscience in 2020. The company expects to more than double its 2019 revenue this year from both existing clients and by leveraging a rich pipeline of prospective additional clients.

The company has already taken steps to increase the reach of its technology via a recent agreement with Cannadips Cannabis (http://ibn.fm/OUJa6). Under the definite agreement, Cannadips will use Lexaria’s technology to enhance its products available in California and nationwide. More specifically, DehydraTECH(TM) will be able to reduce throat irritation normally associated with some terpenes, which are part of the base ingredients of Cannadips THC. The 10-year licensing agreement is expected to considerably improve dipping experience and consumer satisfaction.

The expected revenue increase will support Lexaria’s future growth plans and its new capital markets strategy to qualify for listing on a nationally recognized U.S. exchange. This move is anticipated to significantly increase the company’s market visibility and expand its customer base.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• SRAX’s proprietary platform allows consumers to own, monetize their data
• While CCPA is now law, consumers aren’t feeling protected
• Big marketers looking for correct, effective data; BIGtoken delivers

SRAX Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, has developed a consumer-managed data marketplace that delivers a digital competitive advantage for brands. Through its exclusive platform BIGtoken, SRAX provides everyone in the Internet ecosystem choice with transparency and compensation. Consumers who use BIGtoken are able to own and monetize their data while brands that purchase access to that data benefit from higher ROIs.

Consumers are increasingly demanding to keep their data private. In addition to simply desiring privacy, this movement also stems from a growing awareness of the value of that data. The California Consumer Privacy Act (CCPA) was created in response to the public’s demands. The law took effect on January 1, 2020, and created new consumer rights relating to access, deletion and sharing of personal information collected by businesses. Consumers are concerned that smart devices in their homes are being used to track excessive information and that advertisers have access to that data.

“The goal of the CCPA was to reign in the power that companies like Facebook have over consumers,” SRAX COO Kristoffer Nelson stated in a news release (http://ibn.fm/QbItB). Ironically, Google and Facebook might actually be exempt from the CCPA. Nelson went on to explain that the law was written by well-meaning people who simply did not have a full understanding of the technology, data or advertising.

“The law that was created to challenge big-tech surveillance further entrenches these legacy incumbents while harming small businesses and publishers,” Nelson continued. “But the law is now in effect, and the industry must comply.” The good news is that the law will create a better Internet experience for the consumer by forcing a more transparent and balanced relationship between the consumer and the company.

While the new CCPA regulation has left some tech companies scrambling, SRAX is ahead of the game on this new industry standard. From the outset, the Company believed strongly in putting power in the hands of the consumer – BIGtoken was created on that principle. BIGtoken is seeing three to five thousand new users join daily, a result indicative of today’s consumer’s appreciation for the platform’s open, honest data handling.

Currently, 16.5 million users worldwide have signed into the BIGtoken app, which is available for download in the App and Google Play stores. Through this app, consumers control their own data, deciding for themselves what is and isn’t shared. The consumer manages what companies can buy their data and how that data is used. In turn, this control benefits companies because they are only receiving verified consumer data, allowing them to better reach and serve audiences.

Big marketers aren’t interested in buying bad data anymore. They want information from consumers who are interested in their products, which is exactly the kind of information that SRAX is empowering consumers to take control of.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Lexaria’s fast-acting, high absorption technology will improve dipping experience and consumer satisfaction
• Partnership will enable Lexaria’s to provide its DehydraTECH(TM) drug delivery platform to Cannadips Cannnabis products in California and nationwide
• Cannadips to open one-of-a-kind cannabis oral pouch and dip research facility

Global innovators in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will provide its patented DehydraTECH(TM) technology to Cannadips Cannabis for use on the latter’s market in California and nationwide according to a new definitive agreement. Currently, Cannadips Cannabis Tins are sold in California. Each tin contains 15 pouches with 10 mg of tetrahydrocannabinol each, no nicotine, no tobacco, and all-natural sweeteners. The company also has a high-dose version with 15 pouches and 20 mg of cannabis-derived THC each (http://ibn.fm/N0pdA).

Lexaria’s DehydraTECH(TM) drug delivery platform is perfectly suited to improve the dipping experience through its effective, high absorption technology. Cannadips uses multi spectrum oils as base ingredients. The oils are rich in high-quality terpenes, which ensure the much-coveted entourage effect. DehydraTECH(TM) minimizes the throat irritation usually associated with some terpenes.

“Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,” Chris Bunka, CEO of Lexaria Bioscience Corp., stated in a news release. “Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets.”

The licensing agreement provided by Lexaria grants Cannadips exclusive rights for this product format for the U.S. market for 10 years, with the option to expand the license to Canada, Mexico and/or Europe.

According to Case Mandel, co-founder and chief executive officer of Cannadips Cannabis, the agreement will allow Cannadips to partner with operators in other states and bring its cannabis technology across state lines. “Our cannabis oral pouch and dip research facility in Humboldt is going to be the first of its kind in our brand new 4,000 square foot facility. We are also highly interested in activating the Canadian Oral Pouch Cannabinoid market,” Mandel added. Cannadips’ new 4,000 square foot oral cannabinoid research and development facility in Arcata, California will house manufacturing, corporate offices, distribution, and retail.

Lexaria Bioscience has launched a revolutionary technology that accelerates intestinal absorption of bioactive substances administered without the need for inhalational dosing, co-administration with sweeteners or sugars, and other unhealthy practices. It is applicable to absorption of cannabis and nicotine, among other bioactive substances (http://ibn.fm/GdBAc). The DehydraTECH(TM) drug delivery platform is patented for all non-psychoactive cannabinoids as well as for tetrahydrocannabinol and psychoactive cannabinoids. The platform reduces the time of onset of THC by four times on average (http://ibn.fm/DHOzB).

Lexaria is the leading company in the world that holds patents for oral delivery of all cannabinoids. The company holds 60 globally pending patents. Recently, Lexaria obtained two patents for treating certain conditions including, but not limited to, heart disease, neurological diseases such as Alzheimer’s, Parkinson’s, schizophrenia and others. The technology has potential applications to assist treatment of the common form of dementia as well as other nervous system diseases.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Sigma Labs highlighted in Barron’s as the ‘quality control of the 3-D printing world’.
• 3D printing demand fueled by increasing industry adoption, rising investments.
• 35% annual growth forecast for the foreseeable future.
• SGLB’s PrintRite3D(R) software eliminates quality-assurance barriers to 3D-metal-printing growth; only product of its kind enabling in-process quality control.

Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality-assurance software for the commercial 3D-printing industry, is steadily strengthening its position in the burgeoning additive marketing (AM), or 3D metal printing, space. While forecast numbers vary, a recent “Barron’s” article quotes an industry expert predicting consistent 35% annual growth in the specialized market for the foreseeable future (http://ibn.fm/4FS6K). That growth, said the article, comes as 3D metal printing technology partnered with artificial intelligence offers significant benefits in a wide range of verticals. With its unmatched quality control technology, SGLB appears positioned at the vanguard of an industry poised for explosive growth.

As the applicability of 3D metal printing continues to be realized across an increasingly varied list of industries—from healthcare to aerospace to high-end automotive manufacturing—analysts are struggling to pin down even an approximate estimate for the market’s potential size. Whether it be a question of millions of dollars—or billions—experts are preparing for the next stage in the nascent industry’s evolution (http://ibn.fm/BtRrA).

“We have a market [of] $1 or $2 billion in parts today,” said Claus Emmelmann, head of Germany’s Fraunhofer Institute, a leading institute for development of industrial solutions in additive marketing. That figure only accounts for less than 1% of Emmelmann’s definition for the overall market of metal parts—and Emmelmann believes the market will grow about 35% a year for “a long time,” with 3-D metal printing potentially becoming a $50 billion business by the end of the decade.

While the benefits of 3D metal printing are significant, technological barriers have impeded industrial adoption. “One of the most important problems is qualifying the production of parts,” said Emmelmann, who stressed that the process for designing and qualifying satisfactory parts is expensive and time consuming.

Scaling volume for 3D metal part production has been hampered by this process, leaving industry players seeking a solution. For 3D metal printing to achieve mass adoption, the challenges of low-quality yields and high post-production inspection costs must be resolved. The 3D metal manufacturing quality assurance problem requires a fix that increases yields and deeply cuts post-process inspection costs.

“That’s where . . . Sigma comes in,” the “Barron’s article states. “The small New Mexico-based company sells products to improve quality and validate parts. They are the quality control of the 3-D printing world.”

Sigma has earned this title by creating its exclusive PrintRite3D(R) software, which uniquely provides nondestructive quality assurance during the 3D printing of metal parts. PrintRite3D is the only known additive manufacturing solution that enables in-process quality control of 3D metal printing, allowing errors to be detected and corrected in real time—saving a significant amount of time and money. Due to its reputation and unique ability to remove obstacles impeding the burgeoning industry’s accelerated growth, SGLB has developed a technology that  appears to be essential to enabling the3D metal parts  industry’s rapid growth.

By providing the quality-assurance solution that the 3D metal printing industry needs to transform mainstream manufacturing, SGLB intends to capitalize on the growth in 3D printing across a wide variety of sectors, especially those requiring exacting specifications like aerospace, automotive and biomedical.

Additionally, Emmelmann isn’t the only one with a rosy outlook on the future of 3D metal printing. According to a report by Grand View Research Inc., the global 3D metal printing market size is expected to reach $3.05 billion by 2025, progressing at a CAGR of 31.8% during the forecast period (http://ibn.fm/aLahT).

The Grand View report noted that “increasing adoption of 3D printing as a mainstream manufacturing method and rising investments in research & development (R&D) of 3D metal printing are anticipated to fuel product demand.” The report also observed that “use of 3D metal printing is prominent in the aerospace and defense industry owing to rapid prototyping and manufacturing speed offered by 3D printing.”

To date, Sigma Labs has engaged 19 beta customers with some of the biggest names in the industry, and two of the programs have already awarded Phase 2 contracts for SGLB’s RTE program. SGLB’s advanced computer-aided software, PrintRite3D, revolutionizes the quality control issues for commercial additive manufacturing, and for the first time enables nondestructive quality assurance mid-production–uniquely allowing errors to be corrected in real time. Sigma Labs is delivering key software to unlock the full potential of 3D metal printing and will likely reap the benefits of the sector’s incredible growth.

For more information about Sigma Labs, please visit www.sigmalabsinc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB